
Currently out of the existing stock ratings of Jason Wittes, 100 are a BUY (86.21%), 16 are a HOLD (13.79%).
Analyst Jason Wittes, has had 58.48% of price targets met with an average potential upside of 44.27%, reached in 281 days on average. Previously, Jason Wittes worked at ROTH MKM, AEGIS, LOOP CAPITAL, NORTHLAND CAPITAL MARKETS, BREAN.
Jason Wittes has documented 227 price targets and ratings displayed on 30 stocks. The coverage was on Healthcare, Consumer Cyclical sectors.
Most recent stock forecast was given on IRMD, at 10-Feb-2026.
Analyst best performing recommendations are on PGNX (PROGENICS PHARMACEUTICALS).
The best stock recommendation documented was for NUVA (NUVASIVE) on 6/7/2016. The price target of $60 was fulfilled within 2 days with a profit of $2.11 (3.64%), with a performance score of 18.22.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 08-Jul-2026
4 months 9 days ago
(08-Jul-2026)
1/2 (50%)
$1.4 (233.33%)
277
Buy Since 02-May-2024
$5
1 years 3 months 3 days ago
(14-Aug-2025)
0/2 (0%)
$3.54 (242.47%)
Buy Since 23-May-2016
$7
$9
2 years 6 months 15 days ago
(02-May-2024)
0/8 (0%)
$5.46 (354.55%)
Buy Since 23-Jun-2022
$6.5
3 years 8 days ago
(09-Nov-2023)
0/2 (0%)
$4.06 (166.39%)
Buy Since 08-Nov-2023
$8
$9
3 years 9 days ago
(08-Nov-2023)
0/2 (0%)
$5.34 (200.75%)